The Cigna Group
The Cigna Group (CI) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for The Cigna Group (CI), covering cash flow, earnings, and balance sheets.
The Cigna Group (CI) Income Statement & Financial Overview
Access detailed annual and quarterly income data for The Cigna Group CI financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $65.50B | $65.72B | $62.77B | $60.48B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $65.50B | $65.72B | $62.77B | $60.48B |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $4.21B | $3.87B | $3.59B | $3.68B |
| Operating Expenses | $63.85B | $63.71B | $61.58B | $58.49B |
| Total Costs & Expenses | $63.85B | $63.71B | $61.58B | $58.49B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $362.00M | $362.00M | $376.00M | $375.00M |
| Depreciation & Amortization | $674.00M | $646.00M | $650.00M | $738.00M |
| EBITDA | $2.68B | $3.02B | $2.22B | $3.10B |
| EBITDA Ratio | $0.04 | $0.05 | $0.04 | $0.05 |
| Operating Income | $1.65B | $2.17B | $1.19B | $1.99B |
| Operating Income Ratio | $0.03 | $0.03 | $0.02 | $0.03 |
| Other Income/Expenses (Net) | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Before Tax | $1.65B | $2.009B | $1.19B | $1.99B |
| Income Before Tax Ratio | $0.03 | $0.03 | $0.02 | $0.03 |
| Income Tax Expense | $239.00M | $473.00M | $367.00M | $360.00M |
| Net Income | $1.32B | $1.42B | $739.00M | $1.55B |
| Net Income Ratio | $0.02 | $0.02 | $0.01 | $0.03 |
| EPS | $4.72 | $5.13 | $2.65 | $5.51 |
| Diluted EPS | $4.67 | $5.13 | $2.63 | $5.45 |
| Weighted Avg Shares Outstanding | $280.29M | $277.78M | $278.46M | $281.13M |
| Weighted Avg Shares Outstanding (Diluted) | $283.22M | $277.78M | $281.40M | $284.05M |
Over the past four quarters, The Cigna Group demonstrated steady revenue growth, increasing from $60.48B in Q2 2024 to $65.50B in Q1 2025. Operating income reached $1.65B in Q1 2025, maintaining a consistent 3% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $2.68B, reflecting operational efficiency. Net income dropped to $1.32B, with EPS at $4.72. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan